Journal articles: 'Doxycycline hyclate'

7

Saliy, E. A., A. Yu Honcharuk, O. V. Getalo, and H. V. Tarasenko. "DEVELOPMENT AND EVALUATION OF LYOPHILIZED POWDER TO PREPARE SOLUTION FOR INJECTIONS BASED ON DOXYCYCLINE." Vestnik Farmacii 93, no. 3 (2021): 53–63. http://dx.doi.org/10.52540/2074-9457.2021.3.53.

Full text

Abstract:

The range of doxycycline drugs on the pharmaceutical market of the Ukraine is very limited and is represented by solid forms (capsules and tablets) while a rapid effect and maximum bioavailability of the drug can be provided by parenteral administration. The object of the study is the drug doxycycline hyclate in the form of lyophilisate to prepare solution for injections. During the development of the drug it was taken into account that aqueous doxycycline solution is pH dependent and tends to shift the solution pH during long-term storage. Therefore, excipients such as stabilizer and antioxidant providing buffering properties and stability of the solution were introduced into the composition. According to the research results an optimal composition of lyophilized powder was selected, the production technology with the stage of solution treatment with activated carbon was developed which allowed to obtain lyophilized powder with a well-formed porous mass without splits, cracks and fissures, resistant to shaking, and the prepared solution for parenteral administration is stable by the «Degree of coloration» quality indicator during accelerated storage regimen. It was found that doxycycline hyclate in the form of a lyophilisate shows a wide range of antibacterial activity. Comparative studies in vitro for two drugs, in the form of lyophilisate with doxycycline hyclate for injections and hard gelatin capsules with 100 mg of doxycycline hyclate, confirm equivalence of their bacteriostatic action against bacteria causing infectious diseases in humans.

APA, Harvard, Vancouver, ISO, and other styles

8

White, Cassandra R., Tomasz Z. Jodlowski, Dylan T. Atkins, and Nicole G. Holland. "Successful Doxycycline Therapy in a Patient With Escherichia coli and Multidrug-Resistant Klebsiella pneumoniae Urinary Tract Infection." Journal of Pharmacy Practice 30, no. 4 (2016): 464–67. http://dx.doi.org/10.1177/0897190016642362.

Full text

Abstract:

Objective: To report on a patient with a symptomatic, polymicrobial Escherichia coli and multidrug-resistant (MDR), extended-spectrum β-lactamase (ESBL)-positive Klebsiella pneumoniae urinary tract infection (UTI) who was successfully treated with oral doxycycline hyclate. Case Summary: A 70-year-old white male inpatient with a history of recurrent UTI, type 2 diabetes, hypertension, obesity, and diverticular disease was diagnosed with UTI and empirically treated with oral ciprofloxacin. Symptoms persisted 2 days later, and the patient was transitioned to amoxicillin/clavulanate by a different provider. The next day, upon receipt of the urine culture and susceptibility panel revealing E coli and MDR, ESBL-positive K pneumoniae infection, treatment was switched to doxycycline hyclate, which resulted in clinical improvement. Discussion: Complicated UTI involving multiple pathogens requires careful clinical judgment to select the appropriate antimicrobial agent, improve clinical outcomes, and prevent resistance. Treatment with doxycycline was based on the susceptibility panel and local resistance patterns. Advantages of doxycycline for UTI include its oral formulation, wide spectrum of activity, ability to achieve high concentration in the urine, and low toxicity. Conclusion: Doxycycline hyclate may be an effective treatment option for patients with susceptible MDR UTI.

APA, Harvard, Vancouver, ISO, and other styles

9

Eticha, Tadele, Getu Kahsay, Fitsum Asefa, et al. "Chemometric-Assisted Spectrophotometric Method for the Simultaneous Determination of Ciprofloxacin and Doxycycline Hyclate in Pharmaceutical Formulations." Journal of Analytical Methods in Chemistry 2018 (December 18, 2018): 1–5. http://dx.doi.org/10.1155/2018/9538435.

Full text

Abstract:

Two chemometrics methods—principal component regression and partial least squares—were developed for simultaneous spectrophotometric estimation of ciprofloxacin and doxycycline hyclate in pharmaceutical dosage forms without any pretreatment. The UV spectra of both drugs were recorded at concentrations within their linear ranges between 200 and 400 nm with the intervalsλ= 2 nm at 100 wavelengths in distilled water. Beer’s law was obeyed for both drugs in the concentration ranges of 1–10 μg/mL for ciprofloxacin and 5–25 μg/mL for doxycycline hyclate. Two sets of standard mixtures, 25 as a calibration set and 9 as a validation set, were prepared. The calibration models were evaluated by cross-validation and external validation over synthetic mixtures. The optimized models were successfully applied for chemometric analysis of ciprofloxacin and doxycycline hyclate in synthetic and pharmaceutical mixtures with satisfactory accuracy (recovery values from 97.50% to 101.87%) and precision (RSD < 2%).

APA, Harvard, Vancouver, ISO, and other styles

10

Turk, Erdinc, Orhan Corum, Ibrahim Ozan Tekeli, Fatih Sakin, and Kamil Uney. "Effects of Single and Repeated Doses on Disposition and Kinetics of Doxycycline Hyclate in Goats." Animals 10, no. 6 (2020): 1088. http://dx.doi.org/10.3390/ani10061088.

Full text

Abstract:

The aims of this study in goats were to determine the pharmacokinetics of doxycycline hyclate following single intravenous (IV), intramuscular (IM) and oral administrations of 20 mg/kg and to evaluate the pharmacokinetics and accumulation of doxycycline hyclate after repeated oral administrations at a 20 mg/kg dose every 24 h for 5 days. Six healthy male goats were used for the study. The study was performed in four periods according to a longitudinal study with a 15-day washout period. Plasma concentrations of doxycycline were determined using HPLC-UV and analyzed by a non-compartmental method. IM injection of doxycycline caused swelling and pain due to irritation in the injection site. After IM and oral administrations, terminal elimination half-life (t1/2λz) and mean residence time (MRT) were prolonged and areas under the curve (AUCs) were low. The mean bioavailability of IM and oral administration was 51.51% and 31.39%, respectively. Following repeated oral administration, the accumulation ratio of doxycycline was 1.76. Pharmacokinetic properties including weak accumulation, wide distribution volume and long elimination half-life can make doxycycline hyclate valuable for repeated use via an oral route in the treatment of some infectious diseases in goats. However, the determination of pharmacodynamic effects on susceptible pathogens isolated from goats is also necessary to confirm the drug dosage regimen.

APA, Harvard, Vancouver, ISO, and other styles

11

Sahoo, Pradyumna Kumar, Padmabhusana Sahoo, Jagannath Mohapatra, Debadash Panigrahi, Anup Kumar Patra, and Amiyakanta Mishra. "Development and Validation of Stability Indicating Assay Method of Doxycycline Hyclate by using UV-Spectrophotometer." Journal of Drug Delivery and Therapeutics 13, no. 6 (2023): 89–94. http://dx.doi.org/10.22270/jddt.v13i6.6087.

Full text

Abstract:

In the present study a simple, rapid, sensitive, and cost-effective stability indicating UV- spectrophotometric method was developed of doxycycline hyclate in bulk form and validated as per ICH guidelines. The stability-indicating study of doxycycline hyclate was based on the forced degradation reactions of the drug under different ICH-prescribed stress conditions like acid, alkali, neutral, oxidation, thermal, and photolysis. The absorption maximum of the drug was shown at 270nm and methanol was selected as solvent on the basis of the solubility of the drug. A linear relation with a regression coefficient value (R2) of 0.999 indicates that the method follows Beer’s- Lambert’s law within the concentrations range of 5 - 50µg/ml. The detection limit and quantitation limit were found to be 0.53 µg/ml and 1.55 µg/ml respectively. The % of recoveries was found to be within the range of 98.87 -99.88 with a low % of RSD indicating the accuracy of the method for estimation of the drug. Under stressed conditions, significant degradation was found in alkali, neutral and oxidation conditions and found to be sensitive under thermal and photolytic conditions but stable to acidic hydrolytic conditions. The developed method was validated according to ICH guidelines and found accurate, precise, and specific, suggesting that the developed stability-indicating spectroscopic method could be successfully adopted to estimate doxycycline hyclate. Keywords: Doxycycline Hyclate; Stability Indicating method; UV spectrophotometer; Validation; Stress degradation.

APA, Harvard, Vancouver, ISO, and other styles

12

Mohammad, Adil, Cheng H. Yen, Miah Schneider, et al. "Development and validation of a stability-indicating ultra-performance liquid chromatography (UPLC) method for doxycycline hyclate: an optimization of the analytical methodology for a medical countermeasure (MCM) drug." Analytical Methods 10, no. 16 (2018): 1842–51. http://dx.doi.org/10.1039/c8ay00078f.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Hasan, Kazi Md. Mahmudul, Md. Anwarul Haque, S. M. Alamgir Kobir, and Mobarak Hossain. "Quantification of doxycycline hyclate in different pharmaceutical samples by UV assay." European Journal of Biological Research 6, no. 4 (2016): 275–86. https://doi.org/10.5281/zenodo.163091.

Full text

Abstract:

A simple, selective, linear, precise and accurate ultraviolet detection (UV) method has been developed and applied for the determination of doxycycline hyclate in different pharmaceutical samples. Acid-base analysis and titrimetric method were utilized to determine the value of pH and moisture content of purchased pharmaceutical samples. A mixture of methanol and hydrochloric acid (0.01N methanolic HCl) was used to determine the biochemical properties of doxycycline hyclate. UV detector set at 349 nm was used to monitor the effluent. The purified water was used as solvent. In 1% aqueous solution of doxycycline, three samples (4th, 5th and 7th) showed lower pH values of 1.97, 1.98, and 1.99 respectively. Furthermore, the same samples indicated the additional moisture contents of 2.81%, 2.85% and 2.83% respectively while considering the acceptance level (1.4% to 2.8%). The method proved to be linear (R2 = 0.993), precise (RSD = 0.79% for inter-day precision), accurate (Recovery = 100.59%) and selective regarding possible impurities and excipients of the samples. The doxycycline content obtained in the sample analysis was within the range of 84.05% to 85.80%. The optimized and validated method may be successfully employed to perform routine quality control analyses. Investigation of the pH, moisture content and potency of doxycycline hyclate in different samples give a general view of local pharmacies trade and ensure that the method applied here was validated for this kind of analysis.

APA, Harvard, Vancouver, ISO, and other styles

14

Vilalta, Carles, Tomas Alcala, Rosa Lopez-Jimenez, et al. "Clinical efficacy of acetylsalicylic acid as an adjunct to antibacterial treatment of porcine respiratory disease complex." Journal of Swine Health and Production 20, no. 1 (2012): 10–16. http://dx.doi.org/10.54846/jshap/706.

Full text

Abstract:

Objective: To investigate the efficacy of acetylsalicylic acid (ASA) as an adjunct to antibiotic treatment of pigs with fever during an outbreak of porcine respiratory disease complex (PRDC). Materials and methods: The animals were divided into two groups. The experimental group received doxycycline hyclate and ASA in the drinking water for 5 consecutive days at doses of 10 mg per kg and 100 mg per kg of body weight, respectively, whereas the control group received only doxycycline hyclate (10 mg per kg). Clinical efficacy was investigated by comparing the synergistic or antagonistic effects of ASA administered with an antibiotic versus use of the antibiotic alone to reduce fever or clinical signs or both. Results: Results showed a significant decrease in fever in the group that received ASA and antibiotic versus the values observed in the group that received only antibiotic. No synergistic effect between ASA and doxycycline hyclate was observed to decrease respiratory signs. Implication: Acetylsalicylic acid is efficacious, at least to reduce fever, as an adjunct to antibacterial treatment of PRDC.

APA, Harvard, Vancouver, ISO, and other styles

15

Sharma, Shashi Kant, Poonam, and Nisha Sharma. "Viscometric and Conductometric Studies of Doxycycline Hyclate in Water, Aqueous Glycine and L-Alanine Solutions at Different Temperatures." Asian Journal of Chemistry 31, no. 11 (2019): 2557–66. http://dx.doi.org/10.14233/ajchem.2019.22215.

Full text

Abstract:

To investigate the behaviour of doxycycline hyclate in water, aqueous glycine and aqueous L-alanine solutions, the viscometric and conductometric studies have been conducted at different temperatures. Viscosity data has been used to derive the Jones-Dole viscosity B-coefficient, temperature derivative of B-coefficient (dB/dT), viscosity B-coefficient of transfer (ΔtrB), free energy of activation of viscous flow per mole of solvent (Δμ1 o*) and solute (Δμ2o*) respectively, activation entropy (ΔS2o*) and activation enthalpy (ΔH2o*). Conductance data has been used to compute Walden product (Λm oηo) and temperature coefficient of Walden product (dΛmoηo/dT) for doxycycline hyclate in water, and in aqueous glycine and aqueous L-alanine solution. The positive values of B-coefficient, ΔtrB indicate the prevailing of hydrophilic-ionic interactions in the systems under examination. The negative values of dB/dT and positive values of temperature coefficient of Walden product infer structure maker tendency of doxycycline hyclate in water, and in aqueous glycine and aqueous L-alanine solution. Transfer energy parameters indicate the breaking of intermolecular bonds in transition state which means that formation of activated complex is unfavourable

APA, Harvard, Vancouver, ISO, and other styles

16

Phaechamud, Thawatchai, Nutdanai Lertsuphotvanit, Ngamsil Kabthong, Tiraniti Chuenbarn, Phonpisith Richkamroph, and Kirkphonkij Richkamroph. "FLUID PROPERTIES OF COMPONENTS FOR DEVELOPMENT OF EUDRAGIT RS-BASED IN SITU-FORMING GEL AND MICROPARTICLE AND THEIR PHASE INVERSIONS." Suranaree Journal of Science and Technology 30, no. 5 (2023): 030135(1–10). http://dx.doi.org/10.55766/sujst-2023-05-e02586.

Full text

Abstract:

Solvent exchange-induced in situ-forming gel (isg) and in situ-forming microparticles (ism) have been currently applied as drug delivery approaches for periodontitis treatment. Doxycycline hyclate-loaded Eudragit RS-based isg and ism were prepared in this study. The basic properties such as density, pH, surface/interfacial tension of their solvents including dimethyl sulfoxide (DMSO), N-methyl pyrrolidone (NMP), and 2-pyrrolidone (PYR) in Eudragit RS solution and oils (olive oil and camellia oil) were assessed. This research also tested for apparent viscosity of solvent and drug-free and doxycycline hyclate-loaded ERS-based isg and ism, and their phase transformation rates. Density of PYR was higher than that of DMSO whereas these solvents exhibited the less wettability than oils on glass slide. All fabricated doxycycline hyclate-loaded Eudragit RS-based ism formulations showed good emulsion physical stability with no phase separation for 1 hour. The apparent viscosity of ism was significantly less than that of isg. DMSO-based isg and ism exhibited a significantly less viscosity than that of PYR-based formulations. Rapid phase inversion was evident after isg and ism exposure to agarose gel indicating fast solvent exchange. The loose barrier of camellia oil from its less viscosity facilitated a water diffusion inward Eudragit RS-based ism easier than using viscous olive oil. Solvent exchange-induced doxycycline hyclate-loaded Eudragit RS-based ism using DMSO as the solvent and camellia oil as the continuous phase exhibited various appropriate physicochemical characteristics for applying as drug delivery system for periodontitis treatment.

APA, Harvard, Vancouver, ISO, and other styles

17

Breitschwerdt, Edward B., Barbara C. Hegarty, and Susan I. Hancock. "Doxycycline Hyclate Treatment of Experimental Canine Ehrlichiosis Followed by Challenge Inoculation with Two Ehrlichia canis Strains." Antimicrobial Agents and Chemotherapy 42, no. 2 (1998): 362–68. http://dx.doi.org/10.1128/aac.42.2.362.

Full text

Abstract:

ABSTRACT Dogs were experimentally inoculated with Ehrlichia canis Florida to assess the efficacy of doxycycline hyclate for the treatment of acute ehrlichiosis. Treatment with doxycycline eliminated infection in eight of eight dogs. Untreated infected control dogs appeared to eliminate the infection or, alternatively, suppress the degree of ehrlichiemia to a level not detectable by tissue culture isolation or PCR or by transfusion of blood into recipient dogs. Prior infection did not infer protection against homologous (strain Florida) or heterologous (strain NCSU Jake) strains of E. canis. We conclude that doxycycline hyclate is an effective treatment for acuteE. canis infection; however, these results may not be applicable to chronic infections in nature. Spontaneous resolution of infection, induced by the dog’s innate immune response, provides evidence that an E. canis vaccine, once developed, might potentially confer protective immunity against the organism.

APA, Harvard, Vancouver, ISO, and other styles

18

R, Priya dharshini, Selvi G, Sruthi S, Lakshmi Priya A, and Shyam Sundar S. "Optimization of lyophilization cycle for the formulation and stability assessment of Doxycycline Hyclate." International Journal of Research in Pharmaceutical Sciences 15, no. 4 (2024): 95–110. https://doi.org/10.26452/ijrps.v15i4.4728.

Full text

Abstract:

Background and Aim:Doxycycline hyclate, prone to instability in solution, is unsuitable for liquid dosage forms. Lyophilization, a low-temperature drying process, addresses this limitation by converting the drug into a stable solid. This study aimed to optimize the lyophilization cycle for doxycycline hyclate, enhancing its stability, handling, and transport in injectable form Methods: Pre-formulation studies included solubility analysis, pH determination, water content measurement, FTIR, DSC, photostability, and compatibility studies. Twelve lyophilization cycles were designed, optimizing four formulations by varying temperature, pressure, and cycle duration. Formulations were assessed for cake appearance, solution clarity, pH, reconstitution time, and assay. The optimized formulation underwent additional evaluations for diluent and filter compatibility, in vitro antibacterial activity (disk diffusion), and stability under accelerated and photostabilityconditions.Results:Formulation F3 from Trial 3 exhibited superior performance, with a uniform, smooth cake appearance, clear reconstitution, stable pH, rapid reconstitution time, low water content (0.98%), and minimal organic impurities. Diluent and filter compatibility tests revealed no adverse interactions. The formulation remained stable under light and accelerated conditions, showing dose-dependent antibacterial activity comparable to the innovator’s product.Conclusion:The optimized lyophilization cycle significantly enhanced doxycycline hyclate's stability, handling, and transport. The injectable formulation demonstrated excellent stability, reliable antibacterial activity, and clinical suitability, offering a safer, more convenient alternative to liquid formulations.

APA, Harvard, Vancouver, ISO, and other styles

19

Салій, О. О., Г. Г. Куришко, З. О. Огеренко та О. В. Гетало. "ПОРІВНЯЛЬНІ ДОСЛІДЖЕННЯ ПРОФІЛІВ ВИВІЛЬНЕННЯ ДОКСИЦИКЛІНУ ХІКЛАТУ З ТВЕРДИХ ЖЕЛАТИНОВИХ КАПСУЛ ПРИ ЗМІНІ ВИРОБНИКІВ ДІЮЧОЇ РЕЧОВИНИ". Bulletin of the Kyiv National University of Technologies and Design. Technical Science Series 146, № 3 (2021): 165–74. http://dx.doi.org/10.30857/1813-6796.2020.3.14.

Full text

Abstract:

Comparative studies of the release profiles of doxycycline hyclate from hard gelatine capsules, developed with the active ingredient of alternative manufacturers. The object of the study is samples of the drug doxycycline hyclate in the form of hard gelatin capsules made from an API of an approved manufacturer "Kaifeng Pharmaceutical Group Co. Ltd", China and an alternative manufacturer "HebeiJiupeng Pharmaceutical Co., Ltd.", China. The study of the profiles of the release of the active substance from the drug was carried out using the "Paddle apparatus". The amount of the released substance was determined by the absorption spectrophotometry method.A drug was investigated in hard gelatin capsules of 100 mg based on the substance of doxycycline hyclate from two manufacturers "Kaifeng Pharmaceutical Group Co. Ltd", China, and "HebeiJiupeng Pharmaceutical Co., Ltd", China. It was found that according to the profile of impurities and the results of quality indicators, the substances of doxycycline hyclate from the studied manufacturers are alternative and interchangeable. To confirm the similarity of the dissolution profiles of doxycycline, 100 mg capsules were tested in accordance with the requirements of the State Pharmacopoeia Department, 2.9.3. Dissolution test, using solutions at three pH values: pH 1.0 (0.1 M HCl), pH 4.6 (acetate buffer) and pH 6.8 (phosphate physiological buffer). Comparative studies in vitro for two batches of the medicinal product established the similarity of the kinetics of the release of the active substance. The calculated values of the similarity factor are: f2 = 78.4 for a solution with pH = 1.2; f2 = 82.7 for a solution with pH = 4.6 and f2 = 75.8 for a solution with pH = 6.8. According to studies in three buffer solutions, the similarity coefficient is in the range from 50 to 100, which allows it to conclude that the studied API manufacturers can be used as alternatives for the production of the drug doxycycline hyclate in hard gelatin capsules of 100 mg. The relative standard deviation of the mean (RSD) release rate is less than 20% at the first control point and not more than 10% from the second to the last control point, indicating that the results are valid. It has been proven that the study of the dissolution profiles of solid dosage forms in vitro makes it possible to assess the risks of using APIs synthesized by various manufacturers. The obtained results of the experiment allow manufacturers of finished medicines to reasonably use alternative manufacturers of raw materials to ensure uninterrupted industrial production and meet market demand.

APA, Harvard, Vancouver, ISO, and other styles

20

Салій, О. О., Г. Г. Куришко, З. О. Огеренко та О. В. Гетало. "ПОРІВНЯЛЬНІ ДОСЛІДЖЕННЯ ПРОФІЛІВ ВИВІЛЬНЕННЯ ДОКСИЦИКЛІНУ ХІКЛАТУ З ТВЕРДИХ ЖЕЛАТИНОВИХ КАПСУЛ ПРИ ЗМІНІ ВИРОБНИКІВ ДІЮЧОЇ РЕЧОВИНИ". Bulletin of the Kyiv National University of Technologies and Design. Technical Science Series 146, № 3 (2021): 165–74. http://dx.doi.org/10.30857/1813-6796.2020.3.14.

Full text

Abstract:

Comparative studies of the release profiles of doxycycline hyclate from hard gelatine capsules, developed with the active ingredient of alternative manufacturers. The object of the study is samples of the drug doxycycline hyclate in the form of hard gelatin capsules made from an API of an approved manufacturer "Kaifeng Pharmaceutical Group Co. Ltd", China and an alternative manufacturer "HebeiJiupeng Pharmaceutical Co., Ltd.", China. The study of the profiles of the release of the active substance from the drug was carried out using the "Paddle apparatus". The amount of the released substance was determined by the absorption spectrophotometry method.A drug was investigated in hard gelatin capsules of 100 mg based on the substance of doxycycline hyclate from two manufacturers "Kaifeng Pharmaceutical Group Co. Ltd", China, and "HebeiJiupeng Pharmaceutical Co., Ltd", China. It was found that according to the profile of impurities and the results of quality indicators, the substances of doxycycline hyclate from the studied manufacturers are alternative and interchangeable. To confirm the similarity of the dissolution profiles of doxycycline, 100 mg capsules were tested in accordance with the requirements of the State Pharmacopoeia Department, 2.9.3. Dissolution test, using solutions at three pH values: pH 1.0 (0.1 M HCl), pH 4.6 (acetate buffer) and pH 6.8 (phosphate physiological buffer). Comparative studies in vitro for two batches of the medicinal product established the similarity of the kinetics of the release of the active substance. The calculated values of the similarity factor are: f2 = 78.4 for a solution with pH = 1.2; f2 = 82.7 for a solution with pH = 4.6 and f2 = 75.8 for a solution with pH = 6.8. According to studies in three buffer solutions, the similarity coefficient is in the range from 50 to 100, which allows it to conclude that the studied API manufacturers can be used as alternatives for the production of the drug doxycycline hyclate in hard gelatin capsules of 100 mg. The relative standard deviation of the mean (RSD) release rate is less than 20% at the first control point and not more than 10% from the second to the last control point, indicating that the results are valid. It has been proven that the study of the dissolution profiles of solid dosage forms in vitro makes it possible to assess the risks of using APIs synthesized by various manufacturers. The obtained results of the experiment allow manufacturers of finished medicines to reasonably use alternative manufacturers of raw materials to ensure uninterrupted industrial production and meet market demand.

APA, Harvard, Vancouver, ISO, and other styles

21

Setthajindalert, Orn, Khine Sabel Aung, Juree Charoenteeraboon, Arissarakorn Sirinamaratana, and Thawatchai Phaechamud. "Antibacterial Agent-Incorporated Cholesterol Phase Inversion-Based In Situ Forming Matrix for Crevicular Pocket Delivery." Key Engineering Materials 859 (August 2020): 107–12. http://dx.doi.org/10.4028/www.scientific.net/kem.859.107.

Full text

Abstract:

Phase inversion in situ forming matrix is one of the promising drug delivery systems for periodontitis treatment owing to the prospective high antimicrobial agent level in the gingival crevicular fluid. Typically, this drug delivery system is a fluid polymeric solution that could change simultaneously to matrix-like after injection into aqueous physiological environment. The main propose of the current study was to achieve successful development of antibacterial agent-incorporated cholesterol phase inversion in situ forming matrix for crevicular pocket delivery. In this study, cholesterol was used as a fat matrix former, while N-methyl pyrrolidone (NMP) was used as the solvent and menthol was used as co-solvent. The 10%w/w metronidazole or doxycycline hyclate was employed as the active compounds. The developed formula were evaluated for viscosity and rheological behavior, antimicrobial activity using cup agar diffusion method and in vitro drug release using dialysis tube method. The consistency index from rheological test of doxycycline hyclate and metronidazole-loaded in situ forming matrices was not significantly different (p<0.05). Interestingly, the viscosity of all formula was quite low; thus, this characteristic provoked an ease of injection. They inhibited against Porphyromonasgingivalis efficiently more than cholesterol in situ forming matrix base (p<0.05). Drug release from systems loaded with doxycycline hyclate and metronidazole were rapid and nearly not different. Owing to the apparent efficiently inhibition against Porphyromonasgingivalis the in situ forming matrix loading doxycline hyclate was selected for further development to minimize the burst release and to prolong the drug release.

APA, Harvard, Vancouver, ISO, and other styles

22

Abraham, Woldemichael, Habtamu Abuye, Selass Kebede, and Sultan Suleman. "In Vitro Comparative Quality Assessment of Different Brands of Doxycycline Hyclate Finished Dosage Forms: Capsule and Tablet in Jimma Town, South-West Ethiopia." Advances in Pharmacological and Pharmaceutical Sciences 2021 (February 9, 2021): 1–10. http://dx.doi.org/10.1155/2021/6645876.

Full text

Abstract:

Background. Persistent postmarket quality evaluation helps produce clear information on the current quality status of the different brands of a given drug and hence introduces a biopharmaceutical and therapeutically equivalent list of the products to the prescribers and users of it. This in turn facilitates access to essential medicines by breaking the high-cost barrier imposed by a few expensive brands of the product. This study was aimed at determining the quality and evaluating the equivalence of doxycycline hyclate capsules and tablets in Jimma, Ethiopia. Methods. Ten brands of doxycycline hyclate capsules and tablets were tested for product identity, dosage uniformity, assay, and in vitro dissolution; and tablets were tested for friability and hardness. Results. All investigated brands of doxycycline complied with the USP for dosage uniformity, an assay of the active ingredient, and single-point dissolution tests. One brand, D09, failed both hardness and friability tests. Comparisons of dissolution profiles applying fit factors confirmed that only brands D04, D06, and D07 had similarities with the innovator. Ratio test approaches also showed that significant variability exists between test products and comparators. Weibull model was found to provide the best adjustment curve for all brands, from model-dependent approaches employed for explaining the overall release of drug from the dosage forms. Conclusions. Doxycycline is a biowaiver product. Hence, in vitro dissolution evaluation suffices its market approval. In this quality assessment study, however, the samples passed quality control tests, except D09 brand which failed friability; it has been revealed that five out of eight brands had problems with interchangeability. Only three doxycycline hyclate brands were found to be equivalent to the comparators.

APA, Harvard, Vancouver, ISO, and other styles

23

&NA;. "Doxycycline hyclate recommended for approval in EU." Inpharma Weekly &NA;, no. 1636 (2008): 22. http://dx.doi.org/10.2165/00128413-200816360-00066.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Singh, Garima, Shankar T. Gokhale, Shiva Manjunath, et al. "Evaluation of locally-administered controlled-release doxycycline hyclate gel in smokers and non-smokers in the management of periodontitis: An Indian study." Tropical Journal of Pharmaceutical Research 20, no. 8 (2022): 1739–47. http://dx.doi.org/10.4314/tjpr.v20i8.27.

Full text

Abstract:

Purpose: To assess the clinical and biological effect of locally-administered controlled-release 10 % doxycycline hyclate gel in smokers and non-smokers for the management of periodontitis. Methods: Forty periodontitis patients were enrolled in this study from December 2012 to February 2013 at the Department of Periodontology and Implantology of the Institute of Dental Sciences and Dental Unit of Rohilkhand Medical College, Bareilly, Uttar Pradesh (UP), India. For each patient, probing pocket depth (PPD), clinical attachment level (CAL), plaque index (PI), gingival index (GI), and sulcular bleeding index (SBI) were recorded. Changes in microbial counts were assessed by measuring colonyforming units (CFU) of three major periodontal pathogens. Clinical and microbial parameters were recorded at baseline and one month after scaling and root planing plus controlled local drug delivery of 10 % doxycycline hyclate gel in smokers and non-smokers. Results: A statistically significant change (p < 0.01) in PPD was observed among smokers between baseline (4.26 ± 0.12mm) and re-evaluation at one month (3.20 ± 0.11) with a change of 24.88 %. A statistically significant difference was found between smokers and non-smokers in PPD at the end of a 1-month re-evaluation (p < 0.05). None of the other parameters showed improvement in smokers following treatment. Conclusion: These results indicate that 10 % doxycycline hyclate gel, when administered locally into the periodontal pocket, shows clinical and microbial improvement, among smokers and non-smokers, in the management of periodontitis. Therefore, 10 % doxycycline gel is potentially an effective therapeutic strategy in the management of periodontitis.

APA, Harvard, Vancouver, ISO, and other styles

25

Khaing, Ei Mon, Nutdanai Lertsuphotvanit, Warakon Thammasut, et al. "Cellulose Acetate Butyrate-Based In Situ Gel Comprising Doxycycline Hyclate and Metronidazole." Polymers 16, no. 24 (2024): 3477. https://doi.org/10.3390/polym16243477.

Full text

Abstract:

Cellulose acetate butyrate is a biodegradable cellulose ester bioplastic produced from plentiful natural plant-based resources. Solvent-exchange-induced in situ gels are particularly promising for periodontitis therapy, as this dosage form allows for the direct delivery of high concentrations of antimicrobial agents to the localized periodontal pocket. This study developed an in situ gel for periodontitis treatment, incorporating a combination of metronidazole and doxycycline hyclate, with cellulose acetate butyrate serving as the matrix-forming agent. Consequently, assessments were conducted on the physicochemical properties, gel formation, drug permeation, drug release, morphological topography, and antimicrobial activities of the formulation. The formulation demonstrated an increased slope characteristic of Newtonian flow at higher bioplastic concentrations. The adequate polymer concentration facilitated swift phase inversion, resulting in robust, solid-like matrices. The mechanical characteristics of the transformed in situ gel typically exhibit an upward trend as the polymer concentration increased. The utilization of sodium fluorescein and Nile red as fluorescent probes effectively tracked the interfacial solvent–aqueous movement during the phase inversion of in situ gels, confirming that the cellulose acetate butyrate matrix delayed the solvent exchange process. The initial burst release of metronidazole and doxycycline hyclate was minimized, achieving a sustained release profile over 7 days in in situ gels containing 25% and 40% cellulose acetate butyrate, primarily governed by a diffusion-controlled release mechanism. Metronidazole showed higher permeation through the porcine buccal membrane, while doxycycline hyclate exhibited greater tissue accumulation, both influenced by polymer concentration. The more highly concentrated polymeric in situ gel formed a uniformly porous structure. Metronidazole and doxycycline hyclate-loaded in situ gels showed synergistic antibacterial effects against S. aureus and P. gingivalis. Over time, the more highly concentrated polymeric in situ gel showed superior retention of antibacterial efficacy due to its denser cellulose acetate butyrate matrix, which modulated drug release and enhanced synergistic effects, making it a promising injectable treatment for periodontitis, particularly against P. gingivalis.

APA, Harvard, Vancouver, ISO, and other styles

26

Anna, Dobrova, Golovchenko Olga, and Georgiyants Victoria. "Verification of dissolution test for doxycycline hyclate in capsules to implement into the pharmacopoeial monograph." ScienceRise: Pharmaceutical Science, no. 1(11) (February 28, 2018): 16–20. https://doi.org/10.15587/2519-4852.2018.122975.

Full text

Abstract:

The study of dissolution profiles is important as a cheap and easy supplement to bioequivalence research, and as a variation to such studies. This method is not outlined in the State Pharmacopoeia of Ukraine for the doxycycline capsules. Therefore, according to the current requirements, it was necessary to verify the procedure recommended by the US Pharmacopeia to confirm that this laboratory test will be reproduced correctly, and to use it in our further studies. The aim of our research was to verify the "Dissolution" test analytical procedure for doxycycline hyclate capsules, recommended by the US Pharmacopoeia. Methods. Capsules of doxycycline hyclate 100 mg and set of mineral waters were taken as study objects. A standard sample of doxycycline was used for preparation the comparison solutions. All reagents and test specimens meet the requirements of the SPhU. The experimental data were obtained at the same time in a standardized procedure. For this purpose, 9 points were studied within the range 55-135 % with a step of 10 %. The obtained results were processed statistically in accordance with the requirements of the SPhU. Results. The conducted prediction showed that the total uncertainty of the results of the methodic is 1.04 %, which does not exceed the critical value (3.0 %). To determine the specificity, the effect of placebo was investigated. The calculation showed that the overall effect of placebo on the total absorption of the drug is non-significant (0.51 % ≤ 0.96 %). Also, the method is linear in the range of concentrations from 55 % to 135 %. The systematic error of the results meets the recommended criteria. Conclusions. The analysis of model mixtures of doxycycline hyclate showed the correctness of the investigated method

APA, Harvard, Vancouver, ISO, and other styles

27

Faria, Joice Lara Maia, Thiago Demarchi Munhoz, Carolina Franchi João та ін. "Ehrlichia canis (Jaboticabal strain) induces the expression of TNF-α in leukocytes and splenocytes of experimentally infected dogs". Revista Brasileira de Parasitologia Veterinária 20, № 1 (2011): 71–74. http://dx.doi.org/10.1590/s1984-29612011000100015.

Full text

Abstract:

Canine ehrlichiosis is caused by the bacterium Ehrlichia canis and is characterized by a systemic febrile disease of unknown pathogenesis. This study evaluated the expression of cytokines TNF-α, IL-10, IFN-γ, in splenic cells and blood leukocytes during the acute phase of ehrlichiosis and after treatment with doxycycline hyclate in dogs experimentally infected with the E. canis Jaboticabal strain. The study results showed a significant expression of TNF-α 18 days post-inoculation, reducing by approximately 70% after treatment. There was a unique peak of expression of IL-10 and IFN-γ 18 and 30 days post-inoculation, respectively. This study suggests that TNF-α plays a role in the pathogenesis of the acute phase of canine ehrlichiosis and that treatment with doxycycline hyclate reduces the systemic effects of this cytokine, possibly by reducing or eliminating parasitemia.

APA, Harvard, Vancouver, ISO, and other styles

28

&NA;. "Doxycycline hyclate approved for rosacea in the EU." Inpharma Weekly &NA;, no. 1649 (2008): 21. http://dx.doi.org/10.2165/00128413-200816490-00063.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Dobrova, Anna, Yevhenii Antonenko, Olga Golovchenko, Natalia Harna, Svitlana Garna, and Victoriya Georgiyants. "Development of the method for estimating complex formation using the electrochemical impedance spectroscopy on the example of the doxycycline and iron (III) interaction." ScienceRise: Pharmaceutical Science, no. 1 (29) (February 27, 2021): 31–38. http://dx.doi.org/10.15587/2519-4852.2021.225689.

Full text

Abstract:

The aim. To develop an EIS method for study the interaction between medicinal products and metal salts on the example of the Doxycycline and iron (III) interaction. Materials and methods. Measurements of the total impedance of the studied solutions have been performed using a vector circuit analyzer ZNB40 (Rohde & Schwarz, Germany). The calculations of electrical models were performed using the software package EC-Lab V10.40. Measurement cell was made of Teflon, 1 ml of volume, had 2 parallel nickel plated steel electrodes with diameter 6 mm, distance between electrodes is 9 mm. Basic electrical elements of model circuit were calculated according to type of electrochemical process that were described by Nyquist plot (RW, Rct, RS, Cd, CS etc.). Solutions were prepared immediately before the measurement. Measurements were performed at a temperature of 296±3 K. 6 control solutions of doxycycline and 6 control solutions of iron (III) chloride were prepared and measured. 11 study solutions at a molar ratio 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1 were prepared and measured. Concentration of the solutions was X∙10-3 mol/L respectively. Results. EIS analysis of Nyquist curves of study solutions in the range of molar ratios 1: 6, 1: 5, 1: 4, 1: 3, 1: 2, 1: 1, 2: 1, 3: 1, 4: 1, 5: 1, 6: 1 showed a change in the dynamics of electrical resistance at a ratio of 1:1. In the aqueous solution at T = 296±3 K the constant formation of the solution of doxycycline hyclate and iron (III) chloride is 2.9. This value of the complexation constant indicates that doxycycline hyclate forms a stable metal-ligand complex with iron (III) ions. Conclusions. EIS method can be applied to study the interaction of medicinal products. Model of this study was created on the example of doxycycline hyclate and iron (III) chloride. Metal-ion complexation of these two molecules was once again confirmed by using the EIS method

APA, Harvard, Vancouver, ISO, and other styles

30

Journal, Baghdad Science. "Determination of Doxycycline Hyclate by Batch and Reverse Flow Injection Analysis Based on the Oxidative Coupling Reaction with 3-Methyl-2-benzothiazolinone Hydrazone hydrochloride (MBTH)." Baghdad Science Journal 13, no. 2 (2016): 489–95. http://dx.doi.org/10.21123/bsj.13.2.489-495.

Full text

Abstract:

New, simple and sensitive batch and reverse FIA spectrophotometric methods for the determination of doxycycline hyclate in pure form and in pharmaceutical preparations were proposed. These methods based on oxidative coupling reaction between doxycycline hyclate and 3-methylbenzothiazolinone-2-hydrazone hydrochloride (MBTH) in the presence ammonium ceric sulfate in acidic medium, to form green water-soluble dye that is stable and has a maximum absorbance at 626 nm. A calibration graph shows that a Beer's law is obeyed over the concentration range of 1-80 and 0.5-110 ?g.mL-1 of DCH for the batch and rFIA respectively with detection limit of 0.325 ?g.mL-1 of DCH for r-FIA methods. All different chemicals and physical experimental parameters affecting the development and stability of the colored product were carefully studied. The proposed methods were successfully applied for the determination of DCH in pharmaceutical preparations.

APA, Harvard, Vancouver, ISO, and other styles

31

Kashani-Asadi-Jafari, Fatemeh, and Afra Hadjizadeh. "Niosome-encapsulated Doxycycline Hyclate for Potentiation of Acne Therapy: Formulation and Characterization." Pharmaceutical Nanotechnology 10, no. 1 (2022): 56–68. http://dx.doi.org/10.2174/2211738510666220224103406.

Full text

Abstract:

Background: Acne is the pilosebaceous units' disorder. The most important cause of acne is the colonization of bacteria in the follicles. Among antibiotics, doxycycline hyclate kills a wide range of bacteria. Objectives: The study aims to prevent oral administration's side effects, overcome the barriers of conventional topical treatment, and improve the therapeutic effectiveness; this drug was loaded into niosomal nanocarriers for topical application. Methods: Doxycycline hyclate was loaded into four niosomal formulations prepared by the thinfilm hydration method with different percentages of constituents. Drug-containing niosomal systems were evaluated for morphological properties via scanning electron microscopy, particle size, drug entrapment efficiency, zeta potential, in vitro drug release, physical stability after 60 days, in vitro drug permeation through rat skin, in vitro drug deposition in rat skin, toxicity on human dermal fibroblasts (HDF) by MTT method after 72 hours, and antibacterial properties against the main acne-causing bacteria via antibiogram test. Results: The best formulation had the appropriate particle size of 362.88 ± 13.05 nm to target follicles, entrapment efficiency of 56.3 ± 2.1%, the zeta potential of - 24.46±1.39 mV, in vitro drug release of 54.93 ± 1.99% after 32 hours, and the lowest permeation of the drug through the rat skin among all other formulations. Improved cell viability, increased antibacterial activity, and an approximately three-fold increase in drug deposition were the optimal niosomal formulation features relative to the free drug. Conclusion: This study demonstrated the ability of nano-niosomes containing doxycycline hyclate to treat skin acne compared with the free drug.

APA, Harvard, Vancouver, ISO, and other styles

32

Mittal, Pooja, Shankar T. Gokhale, Shiva Manjunath, et al. "Comparative Evaluation of Locally Administered 2% Gel Fabricated from Lemongrass Polymer and 10% Doxycycline Hyclate Gel as an Adjunct to Scaling and Root Planing in the Treatment of Chronic Periodontitis—A Randomized Controlled Trial." Polymers 14, no. 14 (2022): 2766. http://dx.doi.org/10.3390/polym14142766.

Full text

Abstract:

Background: Extracts of medicinal plant like lemongrass offer a new choice for optional antimicrobial therapy against various oral microorganisms. The objective of this study was to assess, verify, and compare the antimicrobial effectiveness of locally administered 2% lemongrass gel and 10% doxycycline hyclate gel as an adjunct to scaling and root planing (SRP) in treating chronic periodontitis. Method: This is a double-blind parallel arm randomized controlled study. Forty subjects were randomly divided into Group A and B for 2% lemongrass gel and 10% doxycycline hyclate gel, respectively. The clinical assessments of Gingival Index (GI), Plaque Index (PI), Probing Pocket Depth (PPD), and Clinical Attachment Level (CAL) together with microbial colony counts for Porphyromonas gingivalis, Actinomyces naeslundii, and Prevotella intermedia were done at baseline, 1st month, and 3rd month follow-ups. Results: The results showed there was a significant reduction in the mean scores of GI, PPD, and CAL clinical indices from baseline to the 1st and 3rd month follow-ups in both the 2% lemongrass gel and 10% doxycycline gel groups (p < 0.05). Similarly, there was significant reduction in mean CFU scores for all periodontal pathogens from baseline to 1st and 3rd month follow-ups in both the 2% lemongrass gel and 10% doxycycline gel groups (p < 0.05). Conclusions: It could be concluded that the local delivery of 2% lemongrass gel as an adjunct to scaling and root planing is effective and comparable to 10% doxycycline gel in the treatment of chronic periodontitis.

APA, Harvard, Vancouver, ISO, and other styles

33

Schaefer, John J., Glen R. Needham, William G. Bremer, Yasuko Rikihisa, S. A. Ewing, and R. W. Stich. "Tick Acquisition of Ehrlichia canis from Dogs Treated with Doxycycline Hyclate." Antimicrobial Agents and Chemotherapy 51, no. 9 (2007): 3394–96. http://dx.doi.org/10.1128/aac.00358-07.

Full text

Abstract:

ABSTRACT Doxycycline generally alleviates clinical monocytic ehrlichiosis, but its efficacy in the control of monocytotropic ehrlichial pathogens requires further investigation. In this study, Ehrlichia canis was detected in dogs treated with doxycycline for 14 days and in ticks fed on these dogs, suggesting that treated dogs can remain reservoirs for E. canis.

APA, Harvard, Vancouver, ISO, and other styles

34

Lopes-Ferreira, João Vitor, Jullyana Costa Machado, Fernanda Carolina Riberio Dias, et al. "Doxycycline hyclate may damage testicular germinal epithelium in Wistar rats." Bioscience Journal 39 (March 10, 2023): e39031. http://dx.doi.org/10.14393/bj-v39n0a2023-64399.

Full text

Abstract:

Broad-spectrum antimicrobial doxycycline acts as an inhibitor of protein synthesis and it is widely used in the clinical treatment of various infections by microorganisms that are sensitive to the drug, as well as in animal feed. Its liposolubility guarantees its high tissue bioavailability, being associated with several biochemical changes in the organism and potentially adverse effects on reproduction. This study aims to evaluate the effects of the action of doxycycline on spermatogenesis to provide a complete analysis of the tubular and interstitial compartments and to identify possible changes in the testicular parenchyma. Adult male Wistar rats were divided into three groups: one control (water), and two treated with doxycycline at the doses of 10mg/kg and 30mg/kg, for 30 days. After euthanasia and sample processing, the following parameters were evaluated: a) tubular diameter and height of the seminiferous epithelium; b) volumetric proportions (%) and volumes (mL) of the components of the testicular parenchyma; c) counting testicular germ cell populations; d) evaluation of cell viability. The results of the comparative evaluation between the experimental groups demonstrated a significant increase in the diameter and area of the tubular lumen and a reduction in the count of spermatogonia in the experimental group that received doxycycline hyclate at a dose of 30mg/kg. In the same experimental group, an increase in the overall yield of spermatogenesis was found as a consequence of the increase in the mitotic index.

APA, Harvard, Vancouver, ISO, and other styles

35

Anna, Dobrova, Antonenko Yevhenii, Golovchenko Olga, Harna Natalia, Garna Svitlana, and Georgiyants Victoriya. "Development of the method for estimating complex formation using the electrochemical impedance spectroscopy on the example of the doxycycline and iron (III) interaction." ScienceRise: Pharmaceutical Science, no. 1(29) (February 27, 2021): 31–38. https://doi.org/10.15587/2519-4852.2021.225689.

Full text

Abstract:

The aim. To develop an EIS method for study the interaction between medicinal products and metal salts on the example of the Doxycycline and iron (III) interaction. Materials and methods. Measurements of the total impedance of the studied solutions have been performed using a vector circuit analyzer ZNB40 (Rohde & Schwarz, Germany). The calculations of electrical models were performed using the software package EC-Lab V10.40. Measurement cell was made of Teflon, 1 ml of volume, had 2 parallel nickel plated steel electrodes with diameter 6 mm, distance between electrodes is 9 mm. Basic electrical elements of model circuit were calculated according to type of electrochemical process that were described by Nyquist plot (RW, Rct, RS, Cd, CS etc.). Solutions were prepared immediately before the measurement. Measurements were performed at a temperature of 296±3 K. 6 control solutions of doxycycline and 6 control solutions of iron (III) chloride were prepared and measured. 11 study solutions at a molar ratio 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1 were prepared and measured. Concentration of the solutions was X∙10-3 mol/L respectively. Results. EIS analysis of Nyquist curves of study solutions in the range of molar ratios 1: 6, 1: 5, 1: 4, 1: 3, 1: 2, 1: 1, 2: 1, 3: 1, 4: 1, 5: 1, 6: 1 showed a change in the dynamics of electrical resistance at a ratio of 1:1. In the aqueous solution at T = 296±3 K the constant formation of the solution of doxycycline hyclate and iron (III) chloride is 2.9. This value of the complexation constant indicates that doxycycline hyclate forms a stable metal-ligand complex with iron (III) ions. Conclusions. EIS method can be applied to study the interaction of medicinal products. Model of this study was created on the example of doxycycline hyclate and iron (III) chloride. Metal-ion complexation of these two molecules was once again confirmed by using the EIS method

APA, Harvard, Vancouver, ISO, and other styles

36

Verma, Ashish, Rajan Gupta, Nymphea Pandit, and Shweta Aggarwal. "Comparative Evaluation of Subgingivally Delivered 10% Doxycycline Hyclate and Xanthan-based Chlorhexidine Gels in the Treatment of Chronic Periodontitis." Journal of Contemporary Dental Practice 9, no. 7 (2008): 25–32. http://dx.doi.org/10.5005/jcdp-9-7-25.

Full text

Abstract:

Abstract Aim The aim of this study was to evaluate and compare the efficacy of subgingivally delivered 10% doxycycline hyclate and xanthan based chlorhexidine gels when used as an adjunct to scaling and root planing (SRP) in the treatment of chronic periodontitis. Methods and Materials A randomized, controlled, single center study was conducted involving 90 sites in 30 patients suffering from moderate to advanced chronic periodontitis. Each patient contributed three sites which were randomized to three treatment groups: SRP + insertion of doxycycline gel [SRP+DH], SRP + insertion of chlorhexidine gel [SRP+CHX]), and SRP alone [SRP]. Gingival index (GI), plaque index (PI), probing pocket depth (PPD), and clinical attachment level (CAL) were recorded at baseline, 1 month, and 3 months post therapy. Results All treatments showed significant reductions in PPD and CAL at 1 and 3 months when compared to baseline values (p<0.001). At 3 months, sites treated with SRP+DH and SRP+CHX showed an additional reduction in PPD of 0.86 ± 1.0 mm and 0.66 ± 1.58 mm, respectively, significantly greater than SRP alone (p<0.02). Differences in mean PPD reduction between SRP+DH and SRP+CHX were not significant (p=0.46). At 3 months, differences in relative CAL between both SRP+DH (0.80 ± 0.92) and SRP+CHX (0.63 ± 1.47) and SRP alone were statistically significant (p<0.02). Differences in relative CAL between SRP+DH and SRP+CHX were not significant (p=0.54). Conclusion The results suggest treatment with 10% doxycycline hyclate and xanthan based chlorhexidine gels as an adjunct to SRP improves PPD and CAL patients with periodontitis compared to SRP alone. Clinical Significance The use of local drug therapy may refocus the need for surgical periodontal therapy toward deeper pockets. Citation Gupta R, Pandit N, Aggarwal S, Verma A. Comparative Evaluation of Subgingivally Delivered 10% Doxycycline Hyclate and Xanthan-based Chlorhexidine Gels in the Treatment of Chronic Periodontitis. J Contemp Dent Pract 2008 November; (9)7:025-032.

APA, Harvard, Vancouver, ISO, and other styles

37

Elbaramawi, Samar S., Mohamed E. El-Sadek, Mohamed M. Baraka, Lobna M. Abdel-Aziz, and Mahmoud Mohammed Sebaiy. "Instrumental analysis of some anti-ulcer drugs in different matrices." Chemical Reports 2, no. 1 (2020): 156–72. http://dx.doi.org/10.25082/cr.2020.01.005.

Full text

Abstract:

In this literature review, we will introduce most reported methods that have been developed for determination of certain anti-ulcer drugs such as Ranitidine hydrochloride, Famotidine, Omeprazole, Pantoprazole sodium, Tinidazole and Doxycycline hyclate in their pure form, combined form with other drugs, combined form with degradation products, and in biological samples.

APA, Harvard, Vancouver, ISO, and other styles

38

Kogawa, Ana Carolina, Ariana Zoppi, Mario Alfredo Quevedo, Hérida Regina Nunes Salgado та Marcela Raquel Longhi. "Increasing Doxycycline Hyclate Photostability by Complexation with β-Cyclodextrin". AAPS PharmSciTech 15, № 5 (2014): 1209–17. http://dx.doi.org/10.1208/s12249-014-0150-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Sakshi, Shrinath* Aditi Tikait Dr. Swati Deshmukh. "Formulation And Evaluation of Transdermal Patches of Doxycycline for Acne." International Journal of Pharmaceutical Sciences 3, no. 5 (2025): 2516–23. https://doi.org/10.5281/zenodo.15427505.

Full text

Abstract:

The present study focuses on the formulation and evaluation of a transdermal patch containing doxycycline hyclate to provide sustained drug release and improve patient compliance. Patches were prepared using the solvent casting method with various polymers and permeation enhancers. The prepared formulations were evaluated for physicochemical properties, drug content, in-vitro drug release, and ex-vivo skin permeation using Franz diffusion cells. The optimized patch showed good mechanical strength, uniform drug content, controlled drug release, and effective skin permeation. Antibacterial activity was retained, and skin irritation studies confirmed safety. The study concludes that doxycycline transdermal patches offer a promising alternative to oral delivery with enhanced therapeutic benefits. 

APA, Harvard, Vancouver, ISO, and other styles

40

Altoé, Luciana S., Raul S. Alves, Lyvia L. Miranda, et al. "Doxycycline Hyclate Modulates Antioxidant Defenses, Matrix Metalloproteinases, and COX-2 Activity Accelerating Skin Wound Healing by Secondary Intention in Rats." Oxidative Medicine and Cellular Longevity 2021 (April 17, 2021): 1–16. http://dx.doi.org/10.1155/2021/4681041.

Full text

Abstract:

The main objective of this study was to investigate the action of doxycycline hyclate (Dx) in the skin wound healing process in Wistar rats. We investigated the effect of Dx on inflammatory cell recruitment and production of inflammatory mediators via in vitro and in vivo analysis. In addition, we analyzed neovascularization, extracellular matrix deposition, and antioxidant potential of Dx on cutaneous repair in Wistar rats. Male animals ( n = 15 ) were divided into three groups with five animals each (protocol: 72/2017), and three skin wounds (12 mm diameter) were created on the back of the animals. The groups were as follows: C, received distilled water (control); Dx1, doxycycline hyclate (10 mg/kg/day); and Dx2, doxycycline hyclate (30 mg/kg/day). The applications were carried out daily for up to 21 days, and tissues from different wounds were removed every 7 days. Our in vitro analysis demonstrated that Dx led to macrophage proliferation and increased N-acetyl-β-D-glucosaminidase (NAG) production, besides decreased cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE2), and metalloproteinases (MMP), which indicates that macrophage activation and COX-2 inhibition are possibly regulated by independent mechanisms. In vivo, our findings presented increased cellularity, blood vessels, and the number of mast cells. However, downregulation was observed in the COX-2 and PGE2 expression, which was limited to epidermal cells. Our results also showed that the downregulation of this pathway benefits the oxidative balance by reducing protein carbonyls, malondialdehyde, nitric oxide, and hydrogen peroxide (H2O2). In addition, there was an increase in the antioxidant enzymes (catalase and superoxide dismutase) after Dx exposure, which demonstrates its antioxidant potential. Finally, Dx increased the number of types I collagen and elastic fibers and reduced the levels of MMP, thus accelerating the closure of skin wounds. Our findings indicated that both doses of Dx can modulate the skin repair process, but the best effects were observed after exposure to the highest dose.

APA, Harvard, Vancouver, ISO, and other styles

41

&NA;. "Doxycycline hyclate* [Periostat] offers significant benefits for patients with rosacea,." Inpharma Weekly &NA;, no. 1426 (2004): 8. http://dx.doi.org/10.2165/00128413-200414260-00016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Kogawa, Ana Carolina, and Hérida Regina Nunes Salgado. "Quantification of Doxycycline Hyclate in Tablets by HPLC–UV Method." Journal of Chromatographic Science 51, no. 10 (2012): 919–25. http://dx.doi.org/10.1093/chromsci/bms190.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Goren, E., W. A. de Jong, P. Doornenbal, and T. Laurense. "Therapeutic efficacy of doxycycline hyclate in experimentalEscherichia coliinfection in broilers." Veterinary Quarterly 10, no. 1 (1988): 48–52. http://dx.doi.org/10.1080/01652176.1988.9694145.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

İlem-Özdemir, Derya, Evren Gündoğdu, Meliha Ekinci, and Makbule Aşıkoğlu. "Radioactive Permeability Studies of Doxycycline Hyclate from Microemulsion and Solution." MARMARA PHARMACEUTCAL JOURNAL 20, no. 2 (2016): 116. http://dx.doi.org/10.12991/mpj.201620065652.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Christ, Ana Paula, Pauline Trindade Biscaino, Rebeca Lino Lourenço, Alieni Bitencourt de Souza, Estevan Sonego Zimmermann, and Andréa Inês Horn Adams. "Development of doxycycline hyclate suppositories and pharmacokinetic study in rabbits." European Journal of Pharmaceutical Sciences 142 (January 2020): 105141. http://dx.doi.org/10.1016/j.ejps.2019.105141.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Huang, Ying, Zhengwei Huang, Mingjun Wu, et al. "Modified‐release oral pellets for duodenum delivery of doxycycline hyclate." Drug Development Research 80, no. 7 (2019): 958–69. http://dx.doi.org/10.1002/ddr.21575.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Riond, Jean-Luc, and J. Edmond Riviere. "Pharmacokinetics and metabolic inertness of doxycycline in young pigs." American Journal of Veterinary Research 51, no. 8 (1990): 1271–75. http://dx.doi.org/10.2460/ajvr.1990.51.08.1271.

Full text

Abstract:

SUMMARY The disposition of doxycycline hyclate after iv administration of 20 mg/kg of body weight was studied in 6 pigs. Median elimination half-life, estimated in 4 pigs, was 3.92 hours. Mean (± sem) total body clearance was 1.67 ± 0.18 ml/min/kg, and mean apparent volume of distribution at steady state was 0.53 ± 0.04 L/kg. In 2 pigs, secondary peaks in the logarithmic serum concentration-time profile suggested discontinuous enterohepatic cycling, and precluded using these pigs in the pharmacokinetic analysis. The extent of doxycycline binding to serum protein was 93.1 ± 0.2%. Serum or urine from 3 of the pigs was analyzed by use of photodiode array detection and mass spectrometry of a high-performance liquid chromatographic column effluent. These procedures documented lack of doxycycline biotransformation in pigs. It is concluded that, despite an elimination half-life shorter than that reported in other species, doxycycline may be a valuable antimicrobial drug for use in swine practice, pending the development of appropriate formulations.

APA, Harvard, Vancouver, ISO, and other styles

48

Erdene, Enkhtaivan, Enkhjargal Dorjbal, Oidov Baatarkhuu, and Ariunsanaa Byambaa. "Determination of Antimicrobial Activity of Antibiotics Encapsulated in Liposomes." Central Asian Journal of Medical Sciences 10, no. 1 (2024): 8–16. http://dx.doi.org/10.24079/cajms.2024.01.002.

Full text

Abstract:

Objective: Antibiotic-resistant infections caused by bacteria are already a serious concern for humanity, and by 2050, they are most likely to overtake all other causes of death. One of the most frequent causes of skin infections is methicillin-resistant Staphylococcus aureus (MRSA), whose resistance to most medications makes treatment challenging. This study aimed to determine the antibacterial activity of liposome-encapsulated doxycycline compared to free doxycycline. Methods: This study was conducted using an experimental design. Our study isolated and purified the phospholipid (PL) fraction from egg yolk. Antibiotics were encapsulated using the freeze-thaw process, and phospholipids were extracted via intermittent evaporation. Finally, the liposome's minimum inhibitory concentration (MIC) was effective against MRSA. Results: Phospholipid fraction isolated from egg yolks with 32% extraction yield of phosphatidylcholine. The thin phase chromatography fraction was phospholipids with a retention factor (Rf) of 0.39. The effectiveness of liposomal doxycycline hyclate over free doxycycline was demonstrated by in vitro tests. Conclusion: The results showed that a liposome containing phosphatidylcholine could be a tremendous topical antimicrobial construct for treating MRSA infections.

APA, Harvard, Vancouver, ISO, and other styles

49

Phaechamud, Thawatchai, and Juree Charoenteeraboon. "Antibacterial Activity and Drug Release of Chitosan Sponge Containing Doxycycline Hyclate." AAPS PharmSciTech 9, no. 3 (2008): 829–35. http://dx.doi.org/10.1208/s12249-008-9117-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Meijer, L. A., K. G. F. Ceyssens, B. I. J. A. C. de Grève, and W. de Bruijn. "Pharmacokinetics and bioavailability of doxycycline hyclate after oral administration in calves." Veterinary Quarterly 15, no. 1 (1993): 1–5. http://dx.doi.org/10.1080/01652176.1993.9694358.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Doxycycline hyclate'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles